Detalhe da pesquisa
1.
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).
J Viral Hepat
; 31(4): 197-207, 2024 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38243144
2.
Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study.
Clin Infect Dis
; 69(11): 1969-1979, 2019 11 13.
Artigo
Inglês
| MEDLINE | ID: mdl-30715261
3.
Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up.
J Viral Hepat
; 26(1): 109-117, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30187612
4.
Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
J Infect Dis
; 215(7): 1085-1093, 2017 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-28329061
5.
Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
Hepatology
; 61(5): 1512-22, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25348661
6.
Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Gut
; 63(2): 292-9, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-23525574
7.
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Hepatology
; 52(2): 454-61, 2010 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-20683945
8.
A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.
Am J Gastroenterol
; 105(8): 1762-9, 2010 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-20461068
9.
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
Am J Gastroenterol
; 104(10): 2449-57, 2009 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-19584831
10.
Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial.
Circ Cardiovasc Interv
; 9(2): e002376, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26861113
11.
Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders.
Eur J Gastroenterol Hepatol
; 24(9): 1012-9, 2012 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-22668876
12.
Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders.
Liver Int
; 27(9): 1217-25, 2007 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-17919233
13.
Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.
Scand J Gastroenterol
; 41(9): 1087-94, 2006 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-16938723
14.
Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine.
Am J Gastroenterol
; 101(11): 2523-9, 2006 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-17029610